Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

27.09
-1.4300-5.01%
Post-market: 27.090.00000.00%19:20 EDT
Volume:2.29M
Turnover:62.85M
Market Cap:4.31B
PE:-8.92
High:28.50
Open:28.10
Low:26.88
Close:28.52
Loading ...

Company Profile

Company Name:
Ionis Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
1989
Employees:
1069
Office Location:
2855 Gazelle Court,Carlsbad,California,United States
Zip Code:
92010
Fax:
- -
Introduction:
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Directors

Name
Position
Stanley T. Crooke
Chairman, Chief Executive Officer and President
B. Lynne Parshall
Director, Chief Operating Officer and Secretary
Breaux B. Castleman
Director
Frederick T. Muto
Director
Joseph H. Wender
Director
Joseph Klein, III
Director
Joseph Loscalzo
Director
Spencer R. Berthelsen
Director

Shareholders

Name
Position
Stanley T. Crooke
Chairman, Chief Executive Officer and President
B. Lynne Parshall
Director, Chief Operating Officer and Secretary
Brett P. Monia
Senior Vice President, Drug Discovery and Corporate Development
C. Frank Bennett
Senior Vice President, Antisense Research
Elizabeth L. Hougen
Senior Vice President, Finance and Chief Financial Officer
Patrick R. O'Neil
Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
Richard S. Geary
Senior Vice President, Development
Sarah Boyce
Chief Business Officer